New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
05:55 EDTARIA, ARIA, REGN, REGN, ARE, ARE, ZLCS, ZLCS, PFE, PFE, ALNY, ALNY, VSTM, VSTM, SNTA, SNTABoston Biotech Conferences to host a conference
2012 CEO Conference, which was to be held on November 1-2 was rescheduled due to Hurricane Sandy, and is being held in New York on February 13-14.
News For ARIA;REGN;ARE;ZLCS;PFE;ALNY;VSTM;SNTA From The Last 14 Days
Check below for free stories on ARIA;REGN;ARE;ZLCS;PFE;ALNY;VSTM;SNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
08:31 EDTAREAlexandria Real Estate raises quarterly dividend by 6% to 72c
The dividend is payable on October 15 to shareholders of record on September 30.
08:01 EDTALNYAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:27 EDTPFEIBC Life Sciences to hold a conference
Subscribe for More Information
07:27 EDTPFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
07:21 EDTALNYHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
10:32 EDTPFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
08:02 EDTALNYAlnylam broadens pipeline with ALN-AGT
Alnylam Pharmaceuticals announced that it is broadening its pipeline with ALN-AGT. In a poster presented at the American Heart Association’s High Blood Pressure Research 2014 Scientific Sessions, Alnylam and collaborators at the Charite Universitatsmedizin in Berlin presented results of an ALN-AGT lead molecule in an established preeclamptic rodent model. The study showed that administration of ALN-AGT resulted in knockdown of maternal AGT in the liver without detectable evidence of fetal drug exposure, significantly improved pregnancy-related hypertension, ameliorated preeclamptic sequelae in the mother such as proteinuria, and improved fetal outcomes.
September 8, 2014
07:15 EDTREGN, PFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
16:17 EDTAREAlexandria Real Estate, Uber Technologies in JV to acquire and develop parcels
Subscribe for More Information
16:05 EDTPFEPfizer granted orphan status for sickle cell disease drug
Subscribe for More Information
07:23 EDTPFEAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
05:37 EDTREGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 3, 2014
11:30 EDTPFEPfizer has conference call hosted by Bernstein
Subscribe for More Information
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
12:37 EDTARIASarissa says ARIAD denied 'poison pill' waiver request
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use